|
FORBES MEDI-TECH, (FMTI) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Forbes Medi-Tech, Inc., a life sciences company, engages in the research, development, and commercialization of products for the prevention and treatment of cardiovascular disease. It develops cholesterol-lowering agents used both as pharmaceutical therapeutics and functional food ingredients. The companys lead drug candidate is FM-VP4, a cholesterol-lowering prescription pharmaceutical candidate, which completed a Phase II clinical trial in Europe. FM-VP4 is a cholesterol absorption inhibitor, a relatively new class of cholesterol-lowering pharmaceutical that would have therapeutic applications alone or in conjunction with other cholesterol-lowering therapies. The company also markets two nutraceutical products, Reducol and Phyto-S-Sterols. These products are plant sterol-based cholesterol-lowering food and dietary supplement ingredients derived from by-products of the forestry industry. Its drug development program includes FM-VA12, a single molecular entity that has been shown in animal studies to inhibit cholesterol absorption; and FM-VP24, an analogue, which early stage research shows inhibits cholesterol absorption while also exhibiting anti-inflammatory activity. Forbes has strategic partnership with Chusei (U.S.A.), Inc. The company was incorporated in 1985 as Amber Resources, Ltd. and changed its name to Forbes Medi-Tech, Inc. in 1992. Forbes is headquartered in Vancouver, Canada.
|
|
